The Power of Writing, Gabby Rivera | MAKERS
The Power of Writing, Gabby Rivera | MAKERS
The recall of embattled San Francisco District Attorney Chesa Boudin, one of a band of so-called progressive/rogue DAs elected around the country, is gathering significant steam.
Here's how to get the look for less.
Pets can easily bond with humans, but when a wild octopus befriends a diver and becomes his life coach, that true story scores a best documentary nomination for this Sunday's Oscars. Ten years in the making, "My Octopus Teacher" began as a personal video project by South African filmmaker Craig Foster to rekindle his connection with nature by observing an inquisitive female mollusc while free-diving near Cape Town. Foster said his relationship with the octopus taught him about life's fragility and our connection with nature, and even helped him become a better father.
University of Phoenix will hold an in-person commencement ceremony, Saturday, April 24, 2021, at 10:30 a.m., MST at Phoenix’s Chase Field. Featured speakers will be University of Phoenix President Peter Cohen, Provost and Chief Academic Officer Dr. John Woods, and football great and alumnus Larry Fitzgerald. Fitzgerald graduated from the university in 2016 with a Bachelor of Science in Communication, fulfilling a commitment to his mother. The university will adhere to all applicable state, federal and venue guidelines for gatherings by requiring face masks, social distancing and limiting attendance to pre-registered graduates and guests.
The Oscars best picture race might start to look different come 2024 given new Academy standards – or will it? We grade this year's nominees.
The hydroponics market is projected to register a CAGR of 8. 5% over the forecast period, 2021-2026. Considering the force and isolation of COVID 19, strengthening the food production and distribution systems has become a key concern for the future, which has boosted the need for hydroponics farms.New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hydroponics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06062817/?utm_source=GNW As per FAO studies, the development of alternate growing systems such as hydroponics is anticipated to play an important role in global food security by supplying safe and nutritious food. In addition, this can also help in tackling the logistical uncertainties in the market. Thus, the need for hydroponics is anticipated to grow during the forecast period.In 2020, North America was the largest geographic segment of the market studied and accounted for a share of around 35.78% of the hydroponics market. Hydroponics is an environment-friendly and profitable technology. It has been promoted by various governments and non-governmental organizations for its benefits in terms of food security. The need for food supply against the explosive population increase by 2050 has catalyzed the growth of the hydroponics market. Additionally, with the increasing success rates associated with the commercial hydroponics industry and the increasing difficulty of growing crops on soil, the hydroponics market is expanding exponentially.Key Market TrendsHigher Consumption of Salads and VegetablesThe demand for exotic fruits and vegetables has been constantly growing at a higher rate due to the increased purchasing power of consumers. The cost of these exotic products is high, as most of these products are imported, and thus, several research institutions and universities are focusing on establishing more simplified hydroponics systems to accelerate the production of exotic fruits and vegetables and meet the escalating demand. Increasing awareness among the consumers of eating fresh vegetables may also fuel the market in the future. The demand for exotic vegetables like red and yellow capsicum and red lettuce in food and retail chains, like Burger King and KFC, is anticipated to boost sales during the forecast period.North America Dominates the MarketThe demand for fresh vegetables and fruits in the region is driving the market demand for hydroponic operations. At present, the hydroponics farms present in the region are family or small business operations that cover approx. 1 acre. Rooftop hydroponic gardens in urban setups like New York are helping the market grow further. The future growth of the hydroponics market in the region depends greatly on the development of hydroponic production systems that are competitive in cost with systems of open-field agriculture. Hydroponic production has gained popularity among commercial vegetable producers since it is an efficient method to control inputs and manage facilitates for disease and pests and not a labor-intensive method to manage larger areas of production. As hydroponics eliminates the need for soil fumigants and can increase yields of popular vegetables, farmers in the region are anticipated to adopt hydroponics as a popular cultivation method. The increasing adoption of hydroponics as a cultivation method is anticipated to drive the market growth.Competitive LandscapeGlobal Hydroponics input provider market is consolidated with major layers holding a market share of 53.6% and others holding a share of 46.4%. Some of the prominent players operating in the market includes Koninklijke Philips N.V, Argus Control Systems Ltd, American Hydroponics and Hydrodynamics International, Inc.The hydroponic systems output market is highly fragmented, with the top five companies, such as Bright Farms, Inc., FreshBox Farms, Pegasus Agritech, Village Farms International, Inc., and Thanet Earth, among others, cornering just 7.1% of the market share, while the rest of the market is shared among numerous players. Some of which include, Circle Fresh Farms, Green Sense Farms Holdings Inc., and Plenty Unlimited Inc., etc.Reasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06062817/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Clinical trial in U.S. for critically ill COVID-19 patients expected to initiate soon CytoDyn in discussions with Brazil to initiate two COVID-19 trials, one for severe and one for critically ill patients VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has submitted the manufacturing section (CMC) of the application for an Interim Order to Health Canada under a rolling review. This crucial part of the application documents the Company’s manufacturing (CMC) practices are in full compliance with GMP requirements. The Company anticipates the remaining sections will be submitted in the very near future. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “Our entire regulatory team has been working non-stop to complete the submission of the manufacturing section of the Interim Order to Health Canada for leronlimab to be considered as a therapeutic for COVID-19. Our clinical team is working on initiating three trials in parallel. In Brazil, two clinical trial protocols for COVID-19 will be submitted to ANVISA, the Brazilian regulatory authority. In the U.S., we will soon finalize a COVID-19 trial protocol to potentially include a dosage regimen utilizing IV (intravenous) as the first dose and three subcutaneous doses thereafter. We are moving quickly to advance leronlimab along multiple regulatory paths, including securing additional manufacturing from Samsung BioLogics in 2021 and 2022.” About Leronlimab (PRO 140) The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer. The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor important in HIV infection, tumor metastases, and other diseases, including NASH (nonalcoholic steatohepatitis). Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients). Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapies. Cancer research has shown CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. As a result, CytoDyn is conducting two Phase 2 human clinical trials, one in mTNBC, which was granted Fast Track designation by the FDA in 2019, and a second in a basket trial which encompasses 22 different solid tumor cancers. The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers. This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC. It is currently estimated that between 10-30% of those infected with COVID-19 develop long-term sequelae. Common symptoms include fatigue, cognitive impairment, sleep disorders, and shortness of breath. If this trial is successful, CytoDyn plans to pursue clinical trials to evaluate leronlimab’s effect on immunological dysregulation in other post-viral syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis. Preclinical studies revealed a significant reduction in NAFLD and a reduction in liver fibrosis using leronlimab. There are currently no FDA approved treatments for NASH. NASH is a leading cause of liver transplant. About 30 to 40 percent of adults in the U.S. live with NAFLD, and 3 to 12 percent of adults in the U.S. live with NASH. About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has been working diligently to refile its Biologics License Application ("BLA") for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing. CytoDyn expects to refile its BLA in the first half of the calendar year 2021 or shortly thereafter. CytoDyn also completed a Phase 3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension approval. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce the viral burden in people infected with HIV. Moreover, a Phase 2 clinical trial demonstrated that leronlimab monotherapy could prevent viral escape in HIV-infected patients; several patients on leronlimab’s Phase 2 monotherapy extension arm have remained virally suppressed for more than six years. There have been no strong safety signals identified in patients administered leronlimab in multiple disease spectrums, including patients with HIV, COVID-19 and Oncology. CytoDyn is also conducting a Phase 2 clinical trial with leronlimab in mTNBC, a Phase 2 basket trial in solid tumor cancers (22 different cancer indications), Phase 2 investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 Long-Haulers, and a Phase 2 clinical trial for NASH. CytoDyn has already completed two trial in COVID-19 patients (a Phase 2 and a Phase 3) and is in the process of conducting an additional COVID-19 Phase 3 trial for mechanically ventilated critically ill COVID-19 patients. More information is at www.cytodyn.com. Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company's cash position, (ii) the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv) the Company's ability to enter into partnership or licensing arrangements with third parties, (v) the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company's ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company's clinical trials, (viii) the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release. CONTACTSInvestors: Michael MulhollandOffice: 360.980.8524, ext. email@example.com
Meanwhile, Curaleaf Holdings (OTC: CURLF) has delivered a nearly disappointing performance compared to last year. Curaleaf stock is up 16% year to date versus a 90% gain in 2020. Which of these cannabis stocks is the better pick going forward?
The "AC Power Sources - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Apr. 19—Vocational education isn't what it used to be. For one thing, say the words "vo-tech" to someone who works or advocates in the field and you will get some serious stink eye. It's CTE — career and technical education, thank you very much. But there are a lot of other differences. Sure, carpenters are still advised to measure twice and cut once, but all of the various job skills have ...
Several U.S. banks have started deploying camera software that can analyze customer preferences, monitor workers and spot people sleeping near ATMs, even as they remain wary about possible backlash over increased surveillance, more than a dozen banking and technology sources told Reuters. Previously unreported trials at City National Bank of Florida and JPMorgan Chase & Co as well as earlier rollouts at banks such as Wells Fargo & Co offer a rare view into the potential U.S. financial institutions see in facial recognition and related artificial intelligence systems. Widespread deployment of such visual AI tools in the heavily regulated banking sector would be a significant step toward their becoming mainstream in corporate America.
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Meat Extract Market Size, Share & Trends Analysis Report by Type (Chicken, Beef), by Form (Powder, Paste), by Application (Industrial, Commercial), by Region (APAC, North America), and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. The global meat extract market size is expected to reach USD 21.72 billion by 2028, registering a CAGR of 5.2% over the forecast period. The increasing health consciousness among consumers coupled with growing awareness about the importance of protein-rich diets is expected to propel the product demand over the forecast period.The R&D initiatives undertaken by industry players leading to market development powered by economic growth in the developing countries will support market growth. Meat extracts have various applications in the food industry including ready meals, soups, sauces, soup powders, coatings, and seasoning, these applications are increasing both in number and volume as the food industry is introducing new products and expanding into emerging markets.The beef, chicken, and pork type segments accounted for more than 88% of the global volume share in 2020 and are expected to retain similar market capitalization over the forecast period. This growth is credited to the high acceptance and consumption of meats by consumers across the globe. The demand for beef extracts is expected to increase due to the increasing use of the meat to enhance the nutritional value of the products, as it contains nucleotides, minerals & vitamins, organic acids, and amino acids & peptides.North America was the dominant region in 2020 and is expected to retain its position over the forecast period on account of increased consumption of convenience & Ready-To-Eat (RTE) meals. The Asia Pacific is expected to be the fastest-growing regional market over the forecast period as a result of the westernization of diets, rising disposable income levels, and rapid urbanization in emerging economies, such as India and China. The rising focus on leading a healthy and active lifestyle is boosting the sales of products that include meat extracts, which is also boosting the regional market growth.The market participants are both backward and forward integrated, with involvement in the value chain from buying the meat to manufacturing extracts and utilizing them in various food products. For instance, the Knorr brand owned by Unilever sells beef extracts, as well as utilizes the same in its food products including meal mixes and dehydrated soups.Meat Extract Market Report Highlights The chicken type segment led the market, in terms of volume, in 2020 due to its easy availability and low cost of production.However, beef ranked the highest, in terms of revenue, in 2020 due to increased global demand.Based on form, the market is segmented into powder, paste, liquid, and granules. The paste segment is estimated to register the fastest CAGR from 2021 to 2028.This is due to its rising use in various food products, such as pot pies, casseroles, sauces, and stews. Moreover, it is also widely used in commercial food chain restaurants and therefore is expected to have a consistently high demand without any major fluctuations.The industrial application segment, which includes the product usage as flavor and nutrition additive during the production of processed foods, and also in microbial culture as growth promotor, accounted for more than 80% of the overall revenue share in 2020.Asia Pacific is expected to be the fastest-growing regional market over the forecast period.Central & South America is estimated to register the second-fastest CAGR during the forecast years due to high meat consumption coupled with large-scale beef production and exports in the region. Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive SummaryChapter 3. Market Variables, Trends, and ScopeChapter 4. Meat Extract Market: Type Estimates & Trend AnalysisChapter 5. Meat Extract Market: Form Estimates & Trend AnalysisChapter 6. Meat Extract Market: Application Estimates & Trend AnalysisChapter 7. Meat Extract Market: Regional Estimates & Trend AnalysisChapter 8. Competitive LandscapeChapter 9. Company Profiles GivaudanBiospringer by LesaffreHaco Holding Ag.Jbs UsaSmithfield Foods, Inc. (Wh Group Limited)Nippon Ham Group.Essentia Protein SolutionsMaverick BiosciencesBhagwati ChemicalsCarnad Natural TasteFoodex Inti Ingredients, PtTitan Biotech LimitedKanegrade LimitedChimab S.P.A.Inthaco Co. Ltd.Activ International.Idf (International Dehydrated Foods, Inc.)Maverick BiosciencesDiana GroupHenan Yong Da Foods For more information about this report visit https://www.researchandmarkets.com/r/xyhqml CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Apr. 19—Pitt's student-athletes were honored Sunday evening for their achievement in athletics, as well as in the classroom and their community. The Pitt athletics department recognized some of the university's best and brightest in a virtual celebration as part of the fourth annual Panthers' Choice Awards. Herb Douglas, a 1948 Olympic medalist, presented the Heart of a Panther Award to Pitt ...
Apr. 19—The Pittsburgh Pirates are preparing for the impending return of rookie third baseman Ke'Bryan Hayes, and manager Derek Shelton made a double switch on Sunday that possibly foreshadowed their future lineup. Shelton sent Kevin Newman to pinch-hit for Dustin Fowler in the sixth inning against the Milwaukee Brewers. Newman remained in the game at shortstop, with Erik Gonzalez moving from ...
The world's first major travel bubble set up in the Covid pandemic allows quarantine-free visits.
The man was struck by the vehicle at 11:55 p.m. Sunday on Central Park West and West 65th Street.
Apr. 19—In advance of the NFL Draft (April 29-May 1), "Breakfast With Benz" is spending this week publishing daily Steelers draft-related previews. We are breaking down the franchise's needs into five different sections. Monday: Quarterbacks and running backs Tuesday: Receivers and tight ends Wednesday: Offensive line Thursday: Defensive front seven Friday: Secondary Each day, former college ...
As businesses across America develop and start to implement return-to-work plans, Petco Health and Wellness Company, Inc. (NASDAQ: WOOF), a complete partner in pet health and wellness, is urging employers to consider adopting a pet-friendly workplace policy among other post-pandemic changes and sharing information and resources for employees and employers ready to welcome pets at work.
Four drugmakers are set to face trial on Monday in a lawsuit by several large counties in California that are seeking more than $50 billion over claims the companies helped fuel an opioid epidemic by deceptively marketing addictive painkillers. The case against Johnson & Johnson, Teva Pharmaceutical Industries Ltd, Endo International PLC and AbbVie's Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis. Opioids have resulted in the overdose deaths of nearly 500,000 people from 1999 to 2019 in the United States, according to U.S. Centers for Disease Control and Prevention.
Spain's Health Ministry is considering delaying second doses of COVID-19 vaccines for under 80 year olds to maximise the number of people who have received at least one injection, El Mundo newspaper reported on Monday, citing an official document. Under the proposal, patients would receive a second shot of vaccines produced by Pfizer and Moderna eight weeks after the first, rather than the prescribed three-week interval, El Mundo said. The Health Ministry was not immediately available for comment.